{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-053039","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2021-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.990166+00:00","generated_at":"2026-06-28T15:38:55.029068+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"EyePoint appoints Jay S. Duker as COO; $500K base, 305K options","bullets":["Appointed Jay S. Duker, M.D. as COO effective Nov. 1, 2021; he had served as part-time Chief Strategic Scientific Officer since July 2020.","Annual base salary of $500,000; eligible for target annual bonus of 50% of base salary based on performance.","Granted options to purchase 305,000 shares at $11.47, vesting over 4 years; received 15,258 RSUs valued at $175,000 vesting in 1 year.","Received one-time cash award of $175,000 subject to repayment if terminated for cause within one year.","Dr. Duker previously chaired ophthalmology at Tufts Medical Center and co-founded three start-ups including Hemera Biosciences."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-053039","json":"https://secwatch.observer/filing/0001564590-21-053039.json","markdown":"https://secwatch.observer/filing/0001564590-21-053039.md","text":"https://secwatch.observer/filing/0001564590-21-053039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000156459021053039/0001564590-21-053039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000156459021053039/eypt-8k_20211101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T15:38:55.029068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b8505062a2","claim":"Jay S. Duker was appointed as Chief Operating Officer at EyePoint, Inc..","evidence_excerpt":"On November 1, 2021 (the “ COO Start Date ”), EyePoint Pharmaceuticals , Inc. (the “ Company ”) announced that the Board of Directors (the “ Board ”) of the Company appointed Jay S. Duker, M.D., age 63, as the Company's Chief Operating Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1314102/000156459021053039/0001564590-21-053039-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}